10,011 reports of this reaction
19.9% of all GUSELKUMAB reports
#1 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #1 most commonly reported adverse reaction for GUSELKUMAB, manufactured by Janssen Biotech, Inc.. There are 10,011 FDA adverse event reports linking GUSELKUMAB to PRODUCT DOSE OMISSION ISSUE. This represents approximately 19.9% of all 50,420 adverse event reports for this drug.
Patients taking GUSELKUMAB who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is a frequently reported adverse event for GUSELKUMAB, accounting for a significant proportion of all reports.
In addition to product dose omission issue, the following adverse reactions have been reported for GUSELKUMAB:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 10,011 FDA reports for GUSELKUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 19.9% of all adverse event reports for GUSELKUMAB, making it one of the most commonly reported side effect.
If you experience product dose omission issue while taking GUSELKUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.